Emergent New Anti PD-1/PD-L1 Small Molecules for Cancer Treatment
Armen Andreasyan, Luis Mendoza
International Research Journal of Oncology · pp. 18–24 · Published 19 Apr 2022
Abstract
Currently all approved PD-1/PD-L1 inhibitors are monoclonal antibodies. Along with that, compounds from other chemical classes are being investigated as well. Among those are small molecules which demonstrate commensurable therapeutic effect in preclinical and early clinical development. In comparison with antibodies, small molecules have certain advantages such as shorter blood half-times and possibility for oral intake. If clinical trials will confirm acceptable therapeutic and safety profile in forthcoming years, these agents may become good alternatives to the monoclonal antibodies for using in treatment regimens implementing immune checkpoint inhibition via PD-1/PD-L1 pathway.
Cited by 0
No indexed citations yet.
Related research
- Tumor Associated Immune Dysfunction: Immune Cells Involved and Suggested Therapies — shares topic coverage
- Oncolytic Parvoviruses: An Emerging Frontier for Targeted Gene Therapy of Human Carcinoma — shares topic coverage
- Targeting PD-1: A Computational Approach to Discover Small Molecule Inhibitors for Cancer Treatment — shares topic coverage
- Computational Identification of YQG-Like Small-molecule Inhibitors Targeting TIM-3 for Cancer Immunotherapy — shares topic coverage
- The Gut–NET–ICB Axis: Microbial Metabolite-Mediated Regulation of NETosis and Implications for Cancer Immunotherapy — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.